Replimune Group, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a REPL research report →
About the company
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells.
- CEO
- Sushil Patel
- IPO
- 2018
- Employees
- 479
- HQ
- Woburn, MA, US
Price Chart
- Market Cap
- $972.08M
- P/E
- -3.43
- P/S
- 0.00
- P/B
- 6.47
- EV/EBITDA
- -2.52
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -128.57%
- ROIC
- -114.79%
- Revenue
- $0 · 0.00%
- Net Income
- $-313,940,000 · -26.95%
- EPS
- $-3.38 · -10.10%
- Op Income
- $-319,919,000
- FCF YoY
- -43.04%
- 52W High
- $13.24
- 52W Low
- $1.50
- 50D MA
- $6.78
- 200D MA
- $7.30
- Beta
- 0.87
- Avg Volume
- 7.93M
Get TickerSpark's AI analysis on REPL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 1, 26 | Sarchi Christopher | sell | 12,000 |
| May 18, 26 | Xynos Konstantinos | sell | 14,023 |
| May 18, 26 | Schwendenman Andrew | sell | 7,894 |
| May 18, 26 | Sarchi Christopher | sell | 8,626 |
| May 18, 26 | Astley-Sparke Philip | sell | 17,657 |
| May 18, 26 | Patel Sushil | sell | 37,324 |
| May 18, 26 | Hill Emily Luisa | sell | 7,812 |
| Apr 1, 26 | BAKER BROS. ADVISORS LP | other | 44,500 |
| Apr 1, 26 | Sarchi Christopher | other | 50,000 |
| Apr 1, 26 | Sarchi Christopher | other | 75,000 |
Our REPL coverage
Recent articles, reports, and earnings notes.
No research on REPL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate REPL report →Similar companies
Peers in the same neighborhood.